AGIO vs. CTLT, ELAN, ROIV, INSM, LEGN, ASND, CERE, ITCI, JAZZ, and BPMC
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
In the previous week, Agios Pharmaceuticals had 21 more articles in the media than Catalent. MarketBeat recorded 29 mentions for Agios Pharmaceuticals and 8 mentions for Catalent. Agios Pharmaceuticals' average media sentiment score of 1.23 beat Catalent's score of 0.53 indicating that Catalent is being referred to more favorably in the media.
Catalent has higher revenue and earnings than Agios Pharmaceuticals. Catalent is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalent has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Catalent received 161 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. However, 67.46% of users gave Agios Pharmaceuticals an outperform vote while only 59.10% of users gave Catalent an outperform vote.
Catalent has a net margin of -26.61% compared to Catalent's net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of -2.73% beat Catalent's return on equity.
Catalent currently has a consensus price target of $53.14, indicating a potential downside of 5.77%. Agios Pharmaceuticals has a consensus price target of $45.33, indicating a potential downside of 4.78%. Given Catalent's stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Catalent.
Summary
Catalent beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
